Increasing failure of miltefosine in the treatment of kala-azar in nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1530-1538

  Rijal, Suman ^a   Ostyn, Bart ^b   Uranw, Surendra ^a,b   Rai, Keshav ^a   Bhattarai, Narayan Raj ^a   Dorlo, Thomas P C ^c,d,e   Beijnen, Jos H ^c   Vanaerschot, Manu ^b   Decuypere, Saskia ^b   Dhakal, Subodh S ^a   Das, Murari Lal ^a   Karki, Prahlad ^a   Singh, Rupa ^a   Boelaert, Marleen ^b   Dujardin, Jean Claude ^b,f  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

miltefosine; Nepal; parasite drug resistance; relapse; visceral leishmaniasis

Indexed keywords

MILTEFOSINE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BONE MARROW; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMASTIGOTE; PROSPECTIVE STUDY; REINFECTION; RELAPSE; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

MILTEFOSINE; NEPAL; PARASITE DRUG RESISTANCE; RELAPSE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; NEPAL; PARASITE LOAD; PATIENT COMPLIANCE; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT FAILURE;

EID: 84877283879     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit102     Document Type: Article

References (33)

1. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671.
2. Joshi A, Narain JP, Prasittisuk C, et al. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 2008; 45:105-11.
3. World Health Organization South-East Asia Region Office. Regional strategic framework for elimination of kala-azar from the South-East Asia region (2005-2015). New Delhi: WHO, 2005SEA-VBC-85.
4. Epidemiology and Disease Control Division. National strategic guidelines on kala-azar elimination programme in Nepal 2009. Ministry of Health and Population, Government of Nepal: Kathmandu, 2009.
5. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
6. Rijal S, Chappuis F, Singh R, et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 2003; 97:350-4.
7. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
8. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005; 83:394-5.
9. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6:928-34.
10. Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55:543-50.
11. Price RN, Dorsey G, Ashley EA, et al. World antimalarial resistance network I: clinical efficacy of antimalarial drugs. Malar J 2007; 6:119.
12. Alam MZ, Kuhls K, Schweynoch C, et al. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol 2009; 9:24-31.
13. Downing T, Imamura H, Decuypere S, et al. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 2011; 21:2143-56.
14. Downing T, Stark O, Vanaerschot M, et al. Genome-wide SNP and micro-satellite variation illuminate population-level epidemiology in the Leish-mania donovani species complex. Infect Genet Evol 2012; 12:149-59.
15. Rijal S, Bhandari S, Koirala S, et al. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal. Trans R Soc Trop Med Hyg 2010; 104:225-9.
16. Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst 2012; 137:1265-74.
17. World Health Organization South-East Asia Regional Office. Indicators for monitoring and evaluation of the kala-azar elimination programme. TDR/WHO: Geneva, 2010.
18. Dorlo TP, Hillebrand MJ, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865:55-62.
19. Kulshrestha A, Bhandari V, Mukhopadhyay R, et al. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donova-ni. Parasitol Res 2013; 112:825-8.
20. Rahman M, Ahmed BN, Faiz MA, et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 2011; 85:66-9.
21. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223-31.
22. Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of mil-tefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008; 52:2855-60.
23. Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimi-crob Agents Chemother 2012; 56:3864-72.
24. White AC Jr., Castes M, Garcia L, Trujillo D, Zambrano L. Leishman-ia chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection. Am J Trop Med Hyg 1992; 46:123-31.
25. Selvapandiyan A, Dey R, Gannavaram S, et al. Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med 2012; 2012:631460.
26. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amasti-gote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 2009; 53: 3855-9.
27. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006; 9:26-39.
28. Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003; 47:2397-403.
29. Seifert K, Perez-Victoria FJ, Stettler M, et al. Inactivation of the milte-fosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007; 30:229-35.
30. Cojean S, Houze S, Haouchine D, et al. Leishmania resistance to mil-tefosine associated with genetic marker. Emerg Infect Dis 2012; 18:704-6.
31. Bhandari V, Kulshrestha A, Deep DK, et al. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 2012; 6:e1657.
32. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-12.
33. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multi-drug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 2011; 377:477-86.